Abstract
Ingenol mebutate (IM) is approved for the treatment of actinic keratosis and induces cell death in precancerous lesions. The efficacy of IM in the treatment of genital warts was investigated in a therapy-refractory patient. The 74-year-old male was treated with IM gel for three consecutive days. Treatment course and efficacy were evaluated by clinical inspection and non-invasive diagnostics namely optical coherence tomography (OCT) and reflectance confocal microscopy (RCM). Within 24 to 48 hours IM induced a strong local inflammatory reaction. One week later a complete response was observed. OCT and RCM showed a strong reaction after treatment with erosions, swelling of cells, and a subepidermal dark band in representative lesions. IM has the advantage of a short treatment period in contrast to other topical treatments and shows a promising clinical outcome. Larger studies are needed to validate the data.
| Original language | English |
|---|---|
| Pages (from-to) | 434-437 |
| Number of pages | 4 |
| Journal | Annals of Dermatology |
| Volume | 31 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Jan 1 2019 |
Fingerprint
Keywords
- Condylomata acuminata
- Confocal
- Microscopy
- Neoplasms
- Optical coherence tomography
ASJC Scopus subject areas
- Dermatology
Cite this
Successful treatment of genital warts with ingenol mebutate monitored with optical coherence tomography and reflectance confocal microscopy. / Reinholz, Markus; Clanner-Engelshofen, Benjamin M.; Heppt, Markus V.; Hirai, Youji; Ruzicka, Thomas; Berking, Carola; Von Braunmühl, Tanja.
In: Annals of Dermatology, Vol. 31, No. 4, 01.01.2019, p. 434-437.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Successful treatment of genital warts with ingenol mebutate monitored with optical coherence tomography and reflectance confocal microscopy
AU - Reinholz, Markus
AU - Clanner-Engelshofen, Benjamin M.
AU - Heppt, Markus V.
AU - Hirai, Youji
AU - Ruzicka, Thomas
AU - Berking, Carola
AU - Von Braunmühl, Tanja
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Ingenol mebutate (IM) is approved for the treatment of actinic keratosis and induces cell death in precancerous lesions. The efficacy of IM in the treatment of genital warts was investigated in a therapy-refractory patient. The 74-year-old male was treated with IM gel for three consecutive days. Treatment course and efficacy were evaluated by clinical inspection and non-invasive diagnostics namely optical coherence tomography (OCT) and reflectance confocal microscopy (RCM). Within 24 to 48 hours IM induced a strong local inflammatory reaction. One week later a complete response was observed. OCT and RCM showed a strong reaction after treatment with erosions, swelling of cells, and a subepidermal dark band in representative lesions. IM has the advantage of a short treatment period in contrast to other topical treatments and shows a promising clinical outcome. Larger studies are needed to validate the data.
AB - Ingenol mebutate (IM) is approved for the treatment of actinic keratosis and induces cell death in precancerous lesions. The efficacy of IM in the treatment of genital warts was investigated in a therapy-refractory patient. The 74-year-old male was treated with IM gel for three consecutive days. Treatment course and efficacy were evaluated by clinical inspection and non-invasive diagnostics namely optical coherence tomography (OCT) and reflectance confocal microscopy (RCM). Within 24 to 48 hours IM induced a strong local inflammatory reaction. One week later a complete response was observed. OCT and RCM showed a strong reaction after treatment with erosions, swelling of cells, and a subepidermal dark band in representative lesions. IM has the advantage of a short treatment period in contrast to other topical treatments and shows a promising clinical outcome. Larger studies are needed to validate the data.
KW - Condylomata acuminata
KW - Confocal
KW - Microscopy
KW - Neoplasms
KW - Optical coherence tomography
UR - http://www.scopus.com/inward/record.url?scp=85069212244&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069212244&partnerID=8YFLogxK
U2 - 10.5021/ad.2019.31.4.434
DO - 10.5021/ad.2019.31.4.434
M3 - Article
VL - 31
SP - 434
EP - 437
JO - Annals of Dermatology
JF - Annals of Dermatology
SN - 1013-9087
IS - 4
ER -